Billing and Coding: MolDX: BCR-ABL

For BCR-ABL testing, MolDX requires use of CPT 81479 to report multiple tests assigned a single test ID (including NGS translocation analysis reported with one UOS and the MolDX DEX Z-code). The FDA-approved MRDx BCR-ABL test is reported with CPT 0040U, and ABL1 kinase domain mutation analysis for imatinib resistance is reported with CPT 81170 plus one UOS and the DEX Z-code. CPT codes 81206/81207/81208 have reporting restrictions and guidance on single-test versus panel reporting; see MolDX policy A57503 for additional panel/single-gene billing rules.

"When breakpoint testing for BCR-ABL1 is performed as a combination or panel (major, minor, other breakpoints), report multiple tests assigned a single MolDX test ID using CPT 81479."

Sign up to see full coverage criteria, indications, and limitations.